Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 4 · 1996–2026
Showing the 50 most relevant studies, sorted by most relevant.
Y. Ju, Zhu Yan, Hongwei Zhou, et al.
Energy Reports, 2021
Yongping Wu, Baoheng Liu
Sustainability in Environment, 2026
As two important unconventional oil and gas resources, the in-situ pyrolysis technologies of tar-rich Coal and oil shale are key approaches to realize the clean and efficient utilization of resources, alleviate the contradiction between oil and gas supply and demand, and help achieve the “double carbon” goals. Both of them share the core characteristic of being rich in organic matter and convertible into oil and gas products through pyrolysis, yet they exhibit significant differences in resource endowments, pyrolysis characteristics and technological applications. This paper systematically combs the technical principles of in-situ pyrolysis for tar-rich Coal and oil shale, focuses on a comparative analysis of their similarities and differences in pyrolysis kinetics, process routes, key technologies and environmental impacts, and deeply analyzes the common bottlenecks and personalized challenges faced by the current in-situ pyrolysis technologies. It provides theoretical support and practical reference for the optimization and industrial promotion of in-situ pyrolysis technologies for tar-rich Coal and oil shale.
Abstract licence: CC BY 4.0
Mingzhu Sun, Dan Zhang, Q. Yao, et al.
Energy & Fuels, 2018
M. Schmid, H. Korting
Dermatology, 1996
Hengjun Gai, Lin Qiao, Caiyun Zhong, et al.
Journal of Cleaner Production, 2019
Tiantian Jiao, Xizhuang Qin, Huawei Zhang, et al.
Chemical Engineering Research and Design, 2019
Ao Li, Xin Xu, Lianzheng Zhang, et al.
Fuel, 2020
Hongyan Wang, Chunshan Li
2017
Feiyue Gao, Chun Zhou, W. Zihao, et al.
Journal of environmental management, 2023
Yan Zhu, Changcong Li, Husheng Cao, et al.
Fuel, 2025
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.